Submental Fat

14 registered clinical trials studyying Submental Fat.

Status	Trial	Sponsor	Phase
Completed	An Open-label Study That Will Test a Second Treatment Session of RZL-012. NCT05763160	Raziel Therapeutics Ltd.	Phase 2
Completed	Evaluation the Effects of Various Treatments on RZL-012-Induced Adverse Events NCT05476679	Raziel Therapeutics Ltd.	Phase 1 / Phase 2
Completed	Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects NCT05476094	AMIpharm Co., Ltd.	Phase 1
Completed	An Open Label Study That Will Test Safety and Efficacy of RZL-012 Injection Into the Submental Fat in Chinese NCT05466448	Raziel Therapeutics Ltd.	Phase 1 / Phase 2
Completed	Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fat NCT05195112	Medy-Tox	Phase 3
Completed	A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat NCT05154955	10xBio, LLC	Phase 2
Completed	Efficacy and Safety of RZL-012 on Submental Fat Reduction NCT04867434	Raziel Therapeutics Ltd.	Phase 2
Completed	A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Effi NCT04086823	Raziel Therapeutics Ltd.	Phase 2
Completed	A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin ("Doubl NCT04258761	10xBio, LLC	Phase 2
Completed	A Phase II Study to Evaluate the Efficacy and Safety of MT921 in Subjects With Moderate to Severe Submental Fa NCT04144049	Medy-Tox	Phase 2
Completed	Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat NCT03946592	Daewoong Pharmaceutical Co. LTD.	Phase 3
Completed	Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat NCT03005717	Neothetics, Inc	Phase 2
Completed	Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 NCT02163902	Kythera Biopharmaceuticals	Phase 3
Completed	Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 NCT02159729	Kythera Biopharmaceuticals	Phase 2